Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Cash from Financing Activities came in at $30.1 million in Q1 2026, down 73.9% year-on-year from $115.5 million in Q1 2025, and down 71.39% quarter-over-quarter from $105.3 million in Q4 2025.
Oculis Holding AG (OCS) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Oculis Holding AG's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at $30.1 million for Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 73.9% year-over-year to $30.1 million in Q1 2026; TTM through Mar 2026 was $134.1 million, a 23.41% decrease from a year earlier, with the FY2025 full-year figure at $225.4 million, up 267.45% from the prior year.
- Cash from Financing Activities slipped to $30.1 million in Q1 2026 per OCS's latest filing, from $105.3 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $115.5 million in Q1 2025 and bottomed at -$2.1 million in Q3 2025.
- The 5-year median for Cash from Financing Activities is $2.0 million (2022), against an average of $30.2 million.
- Across the five-year window, Cash from Financing Activities sank 264.05% in 2024 and jumped 58848.04% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at -$288570.1 in 2022, then surged by 264.08% to $473488.9 in 2023, then surged by 549.73% to $3.1 million in 2024, then surged by 3324.12% to $105.3 million in 2025, then plunged by 71.39% to $30.1 million in 2026.
- Per Business Quant, the three latest OCS Cash from Financing Activities figures stand at $30.1 million (Q1 2026), $105.3 million (Q4 2025), and -$2.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 238.74 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 15.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.14 Mn |
| Mar 31, 2026 | 30.14 Mn |
| Dec 31, 2025 | 105.34 Mn |
| Dec 31, 2025 | 105.34 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Sep 30, 2025 | -2.14 Mn |
| Jun 30, 2025 | 730,773.59 |
| Jun 30, 2025 | 730,773.59 |
| Mar 31, 2025 | 115.49 Mn |
| Mar 31, 2025 | 115.49 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Dec 31, 2024 | 3.08 Mn |
| Sep 30, 2024 | -850,650.74 |
| Sep 30, 2024 | -850,650.74 |
| Jun 30, 2024 | 57.33 Mn |
| Jun 30, 2024 | 57.33 Mn |
| Mar 31, 2024 | 195,911.68 |
| Mar 31, 2024 | 195,911.68 |
| Dec 31, 2023 | 473,488.88 |
| Dec 31, 2023 | 473,488.88 |